PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period
Melbourne, 5 November 2020 – PolyActiva Pty Ltd, a clinical-stage Australian ophthalmology biopharmaceutical company, today announced it has successfully completed its Phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings….
PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors
Melbourne, Australia – 30 October 2020: PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, today announced the appointment of a highly experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company’s Board of Directors. Ms Valorie is recognized in the industry for her success in…
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
July 23, Chicago – PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma…
PolyActiva commences its first Phase I clinical trial
PolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently recruited first patients into its Phase I clinical study designed to show its glaucoma implant is safe and well tolerated…
PolyActiva raises AUD$9.2M in Series B venture funding
PolyActiva announced today that it has raised AUD $9.2 Million in a Series B financing round from a consortium of investors including the Medical Research Commercialisation Fund (MRCF) and Brandon Biosciences Fund 1 (BBF1) (both managed by Brandon Capital), Yuuwa Capital and additional participation from angel investors.